Apocrine subtype of TNBC typically has a better prognosis but a poorer response to chemotherapy. Since this is a rarer subtype, most of the evidence comes from real-world experience and anecdotal reports. Smaller data sets have suggested that AC-T may not be needed in these patients and docetaxel an...

Precisely because this is a rare subtype, neoadjuvant chemo immunotherapy should be used, otherwise we are blind to the outcome. Triple negative disease biology supports this approach. In ER-negative disease, neoadjuvant therapy should be the primary strategy because path CR correlates with ou...